Genentech’s Tecentriq Plus Avastin Combo reduces the risk of cancer coming back
genetic engineeringa unit of Roche Holding Ltd RHHBYannounced that the phase 3 study IMbrave050 reached its primary endpoint of recurrence-free survival (RFS) at the pre-specified